Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD228-targeted antibody-drug conjugate

DRUG CLASS:

CD228-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MFI2 expression	Triple Negative Breast Cancer	MFI2 expression	Triple Negative Breast Cancer	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D
MELTF expression	Solid Tumor	MELTF expression	Solid Tumor	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D
MELTF overexpression	Triple Negative Breast Cancer	MELTF overexpression	Triple Negative Breast Cancer	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D
MELTF overexpression	Lung Non-Small Cell Squamous Cancer	MELTF overexpression	Lung Non-Small Cell Squamous Cancer	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D
MELTF overexpression	Melanoma	MELTF overexpression	Melanoma	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D	SGN-CD228A Sensitive: D – Preclinical SGN-CD228A Sensitive : D